Clinical Trial Update: A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating KIN-2787 in participants with BRAF and/or NRAS mutation-positive solid tumors. The study includes patients with non-small cell lung c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma
• Non-small Cell Lung Cancer

Drugs mentioned

• KIN-2787

Snippet

Sponsor: Pierre Fabre Medicament | Conditions: Solid Tumor, Adult, Non-small Cell Lung Cancer | Phase 1 | Status: ACTIVE_NOT_RECRUITING